Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ardelyx Inc (ARDX)

Ardelyx Inc (ARDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,159,400
  • Shares Outstanding, K 236,854
  • Annual Sales, $ 124,460 K
  • Annual Income, $ -66,070 K
  • EBIT $ -64 M
  • EBITDA $ -63 M
  • 60-Month Beta 0.92
  • Price/Sales 9.65
  • Price/Cash Flow N/A
  • Price/Book 7.59

Options Overview Details

View History
  • Implied Volatility 78.36% ( -2.35%)
  • Historical Volatility 88.63%
  • IV Percentile 50%
  • IV Rank 41.88%
  • IV High 169.26% on 02/22/24
  • IV Low 12.86% on 06/10/24
  • Put/Call Vol Ratio 0.68
  • Today's Volume 4,615
  • Volume Avg (30-Day) 4,647
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 131,525
  • Open Int (30-Day) 118,256

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.01
  • Number of Estimates 7
  • High Estimate 0.04
  • Low Estimate -0.04
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +108.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.34 +5.75%
on 11/11/24
6.53 -29.71%
on 11/07/24
-1.45 (-24.01%)
since 10/11/24
3-Month
4.34 +5.75%
on 11/11/24
7.18 -36.07%
on 09/27/24
-1.23 (-21.13%)
since 08/12/24
52-Week
3.49 +31.52%
on 11/13/23
10.13 -54.69%
on 02/12/24
+1.03 (+28.93%)
since 11/10/23

Most Recent Stories

More News
Ardelyx Responds to District Court Decision Granting Motion to Dismiss

ARDX : 4.59 (-6.23%)
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference

ARDX : 4.59 (-6.23%)
Ardelyx: Q3 Earnings Snapshot

Ardelyx: Q3 Earnings Snapshot

ARDX : 4.59 (-6.23%)
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update

ARDX : 4.59 (-6.23%)
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates

Amarin Corporation plc AMRN reported an adjusted loss of 5 cents per share for the third quarter of 2024, which was in line with the Zacks Consensus Estimate. The company had reported breakeven earnings...

FOLD : 10.49 (-1.87%)
AMRN : 0.5500 (-1.79%)
ARDX : 4.59 (-6.23%)
ATNM : 1.8000 (-6.74%)
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

Corcept Therapeutics Incorporated CORT reported third-quarter 2024 earnings of 41 cents per share, which significantly beat the Zacks Consensus Estimate of 27 cents. The company had reported earnings of...

FOLD : 10.49 (-1.87%)
CORT : 57.79 (-2.15%)
ARDX : 4.59 (-6.23%)
ATNM : 1.8000 (-6.74%)
Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting

ARDX : 4.59 (-6.23%)
Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week

ARDX : 4.59 (-6.23%)
Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community

ARDX : 4.59 (-6.23%)
Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community

ARDX : 4.59 (-6.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase...

See More

Key Turning Points

3rd Resistance Point 5.32
2nd Resistance Point 5.12
1st Resistance Point 4.86
Last Price 4.59
1st Support Level 4.39
2nd Support Level 4.19
3rd Support Level 3.93

See More

52-Week High 10.13
Fibonacci 61.8% 7.59
Fibonacci 50% 6.81
Fibonacci 38.2% 6.03
Last Price 4.59
52-Week Low 3.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar